1-(4-pyridylmethyl)benzimidazole | 934522-26-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 1-(4-pyridylmethyl)benzimidazole
• 英文别名: 1-(pyridin-4-ylmethyl)-1H-benzo[D]imidazole；pmbm；N-(4-pyridylmethyl)benzimidazole；1-(4-pyridylmethyl)-1H-benzimidazole；1-(4-Pyridylmethyl)-1h-benzimidazole；1-(pyridin-4-ylmethyl)benzimidazole
• CAS: 934522-26-6
• 化学式: C₁₃H₁₁N₃
• mdl: MFCD26145119
• 分子量: 209.25
• InChiKey: LKMVCNDDXRCGIW-UHFFFAOYSA-N

物化性质

• 熔点：
  50 °C
• 沸点：
  424.4±47.0 °C(Predicted)
• 密度：
  1.18±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.076
• 拓扑面积：
  30.7
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(4-pyridylmethyl)benzimidazole 、 1,4-二碘四氟苯 以 甲醇 为溶剂， 生成
  参考文献：
  名称：

  静电势差和卤素键选择性

  摘要：

  通过对9个全氟化卤素键供体和12个对位受体进行系统性共结晶，探讨了基于分子静电势的卤素键相互作用选择性的指南，该两个单体呈现出两个具有不同静电势的结合位点。108个反应中总共89个导致共晶形成（如IR光谱所示），获得了35个新的晶体结构。为了避免在这些实验中出现任何潜在的溶剂-溶质偏差，甲醇专门用作晶体生长的溶剂。根据每种情况下观察到的卤素键连接性的具体性质，将结构分为三个不同的组。每个分子上两个受体位点之间的静电势差定义为ΔE值。第1组包含ΔE值低于35kJ / mol单位的受体分子，并且在该类别中，卤素键发生在所有共晶体（9/9）的两个结合位点上。第2组中的对位受体分子的特征在于ΔE值在35–65 kJ / mol范围内，在该组中，一半的结构显示卤素键与最佳受体（11/22），一半的结构显示卤素键与最佳受体。两个结合位点（11/22）。在第3组中，ΔE值＞ 167kJ / mol，并且

  DOI：

  10.1021/acs.cgd.5b01770
• 作为产物：
  描述：

  苯并咪唑 、 4-氯甲基吡啶盐酸盐 在 sodium hydroxide 作用下， 以 乙腈 为溶剂， 反应 9.0h， 以69.4%的产率得到1-(4-pyridylmethyl)benzimidazole
  参考文献：
  名称：

  用于晶体工程目的的羟基苯甲酸相对氢键强度排名

  摘要：

  导致总共六个新的晶体结构的任一涉及3-羟基或4-羟基苯甲酸系统的共结晶，由下式计算分子静电势的表面上和现有的结构数据的补充，已经表明，在有竞争力的分子识别的情况， OH OH OH COOH is是一个更有效的氢键供体，这反过来凸显了静电荷比酸度可提供更多有用的指导来预测竞争性氢键偏好。

  DOI：

  10.1002/chem.201301402

文献信息

• TNF -Alpha Modulating Benzimidazoles
  申请人：UCB Biopharma SPRL

  公开号：US20150152065A1

  公开（公告）日：2015-06-04

  A series of benzimidazole derivatives, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

  一系列苯并咪唑衍生物，作为人类肿瘤坏死因子α活性的强效调节剂，因此在治疗和/或预防各种人类疾病方面具有益处，包括自身免疫和炎症性疾病；神经和神经退行性疾病；疼痛和痛觉障碍；心血管疾病；代谢性疾病；眼科疾病；以及肿瘤学疾病。
• Syntheses, structures, photoluminescence of four dicarboxylate-controlled Zn(II) coordination complexes incorporating flexible 1-(4-pyridylmethyl)-benzimidazole ligand
  作者：Hong-Jun Hao、Ming-Yue Du、Dan-Feng Wang、Cheng-Jie Sun、Zhan-Hui Wang、Rong-Bin Huang、Lan-Sun Zheng

  DOI：10.1016/j.molstruc.2013.05.034

  日期：2013.9

  Four Zn(II) coordination complexes, namely [Zn(pmbm)(2)(tpa)]center dot H2O}(n) (1), [Zn(pmbm)(phda)]center dot 2(H2O)}(n) (2), [Zn(pmbm)(aze)](n) (3), [Zn(pmbm)(1,4-ndc)]center dot 2(CH3OH)}(n) (4) [pmbm = 1-(4-pyridylmethyl)-benzimidazole, H(2)tpa = terephthalic acid, H(2)phda = phenylenediacetic acid, H(2)aze = azelaic acid, 1,4-ndcH(2) = 1,4-naphthalenedicarboxylic acid] have been synthesized by solution phase ultrasonic reactions of Zn(AC)(2)center dot 2H(2)O with pmbm and various dicarboxylates ligands under the ammoniacal condition. All the complexes have been characterized by elemental analyses, IR spectra and X-ray diffraction. Complexes 1 and 2 exhibit one-dimensional chains structure and complex 3 and 4 are two-dimensional sheets structure with (4,4) topology. Complexes 1-4 spanning from one-dimensional chains to two-dimensional sheets suggest that dicarboxylates play significant roles in the formation of such coordination architectures. The photoluminescences of the complexes were also investigated in the solid state at room temperature. (c) 2013 Elsevier B.V. All rights reserved.
• Synthesis structure and luminescence of a double helical coordination polymer with a semirigid ligand: L=N-(4-pyridylmethyl)benzimidazole
  作者：Meihua Huang、Ping Liu、Jian Wang、Yun Chen、Zheng Liu、Qingyan Liu

  DOI：10.1016/j.inoche.2006.06.010

  日期：2006.9

  With the ligand: N-(4-pyridylmethyl)benzimidazole having some flexibility and spacial hindrance, one-dimensional double helix with the chirality, ([AgL] center dot NO3). (1), which was synthesized by the diffusion reaction in a U-tube with H2O as diffusion mediate, is constructed by two single-helical chains with the same chirality through van der Waals forces. But the compound 1 is racemic. (C) 2006 Elsevier B.V. All rights reserved.
• Zinc(II) and mercury(II) coordination architectures with two pyridyl/benzimidazol-1-yl-based ligands: Crystal structures and photoluminescent properties
  作者：Jun-Jie Wang、Li-Fen Yan、Zuo-Xi Li、Ze Chang、Tong-Liang Hu、Xian-He Bu

  DOI：10.1016/j.ica.2009.02.013

  日期：2009.7

  In our efforts to investigate the relationships between the structures of ligands and their complexes, two structurally related ligands, 1-(2-pyridylmethyl)-1H-benzimidazole (L-1) and 1-(4-pyridylmethyl)-1H-benzimidazole (L-2), and their four complexes, [Zn(L-1)(2)Cl-2] (1), [Hg(L-1)Br-2](infinity) (2), [Zn(L-2)Cl-2](CH3CN)}(infinity) (3) and [Hg(L-2)Br-2](2)(CH3CN)(2) (4) were synthesized and structurally characterized by elemental analyses, IR spectra and single-crystal X-ray diffraction analysis. Structural analyses show that 1 has a mononuclear structure, and 2 and 3 both take 1D structure. While 4 takes a dinuclear structure. 1, 2 and 4 were further linked into higher-dimensional supramolecular networks by weak interactions, such as C-H center dot center dot center dot Cl and C-H center dot center dot center dot Br H-bonding, C-H center dot center dot center dot pi, and pi center dot center dot center dot pi stacking interactions. The structural differences of 1-4 may be attributed to the difference of the spatial positions of the terminal N donor atoms in the pendant pyridyl groups in L-1 and L-2, in which the pyridine rings may act as the directing group for coordination and the benzimidazole rings act as the directing group for pi center dot center dot center dot pi stacking and C-H center dot center dot center dot pi interactions. The luminescent properties of the corresponding complexes and ligands have been further investigated. (C) 2009 Elsevier B. V. All rights reserved.
• TNF -ALPHA MODULATING BENZIMIDAZOLES
  申请人：UCB Biopharma SPRL

  公开号：EP2858983A1

  公开（公告）日：2015-04-15